MicroPort Scientific Corporation

10/17/2021 | Press release | Archived content

Clinical Trial Enrollment Completed for the First Endovastec™ Venous Stent

Beijing, China, 16 October 2021 - Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd. (Endovastec™) recently completed the final procedure of the pre-market multicenter clinical trial for the Vflower® Venous Stent System in Beijing, marking the completion of patient enrollment in the trial. The clinical trial for the Vflower® Venous Stent System is a prospective, multi-center, single-arm, nationwide clinical study led by Peking Union Medical College Hospital, in conjunction with The Affiliated Hospital of Qingdao University, and 12 medical centers as co-participators in China. It took just 10 months from the first implantation to the enrollment completion.

The Vflower® Venous Stent System is the first venous product developed by Shanghai Bluevastec MedTech Co., Ltd. (BluevastecTM), a subsidiary of EndovastecTM. Bluevastec™ leveraged the long-established technological foundation of Endovastec™ in vascular stents and delivery devices, coupled with in-depth research on venous morphological characteristics and hemodynamics for the design of this product. Vflower® features a braided structure that provides sufficient support to iliac vein compression and meets the flexibility requirement of distal vein. In addition, the unique design of its delivery system ensures a stable and precise release.

Existing follow-up results show that the Vflower® Venous Stent System has a 100% success rate in terms of device, technical and procedural success. This indicates that the System is able to precisely locate and effectively support the lesion site during a procedure to ensure unobstructed blood flow, as well as the stent's conformity to the physiology of the iliac vein. The completion of this clinical implantation of the Vflower® Venous Stent System fills a gap in the market of domestic venous stents, providing much needed assistance to patients.

Dr. Zhenyu Yuan, Vice President of Endovastec™ and General Manager of Bluevastec™, stated, "Bluevastec™ will continue to focus on developing more venous products and strengthen its product portfolio in this space through in-depth basic research and rich clinical research data to offer more cost-effective solutions for more patients with venous diseases. "

About Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), which is a subsidiary of MicroPort Scientific Corporation, was founded in Shanghai SIMZ Century Medicine Park in 2012. Endovastec™ was granted Shanghai High-tech Enterprises, Shanghai Science and Technology Little Giant Enterprise, and the first batch of Specialized and New "Little Giant" Enterprise, AAA-level Credit Enterprise and Multinational R&D Center in China. Endovastec™ was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019.